Latest The New England Journal Stories
SILVER SPRING, Md., Nov. 25 /PRNewswire-USNewswire/ -- An article by Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research, titled "A Difficult Balance - Pain Management, Drug Safety, and the FDA," appears in the Nov.
Following one of the largest studies ever conducted in Parkinson's disease (PD), researchers at Mount Sinai School of Medicine report today in The New England Journal of Medicine that rasagiline, a drug currently used to treat the symptoms of PD, may also slow the rate of disease progression.
The source of PML, the JC virus, is found to be reactivated in multiple sclerosis patients receiving natalizumab treatment.
Increased use of medical scans could have a dangerous impact on the health of Americans under age 65, according to a recent study.
The new chiefs of the Food and Drug Administration stated that the recent salmonella outbreak from peanut butter was representative of a failure by the agency - one they are focused on repairing.
The afflictions of impoverished Cambodia can be seen in the nationâ€™s western corner: girls for hire standing outside restaurants, uneven dirt roads dotted with signs that warn â€œDanger Mines!â€
A team of scientists has discovered a new syndrome associated with severe congenital neutropenia (SCN), a rare disorder in which children lack sufficient infection-fighting white cells, and identified the genetic cause of the syndrome: mutations in the gene Glucose-6-phosphatase, catalytic subunit 3 (G6PC3).
A study has found that surgery is no better than more conservative treatment to relieve knee pain caused by arthritis.
Iowa Senator Charles Grassley said yesterday that Dr. Steven M. Haffner, a well-known diabetes expert at the University of Health Science Center in San Antonio, had leaked confidential, unpublished information to GlaxoSmithKline (GSK) that questioned the safety of the companyâ€™s diabetes drug Avandia.